J. Lipid Res. Did you know there is a large type edition? Click here.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


A more recent version of this article appeared on July 1, 2007

Papers In Press, published online ahead of print April 24, 2007
J. Lipid Res., doi:10.1194/jlr.M600480-JLR200
This Article
Right arrow Full Text (Accepted Manuscript)
Right arrow All Versions of this Article:
M600480-JLR200v1
48/7/1533    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ibrahim, S.
Right arrow Articles by Ponsin, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ibrahim, S.
Right arrow Articles by Ponsin, G.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Submitted on November 8, 2006
Revised on April 18, 2007
Accepted on April 23, 2007

The transfer of very low density lipoprotein- associated phospholipids to activated human platelets depends upon cytosolic phospholipase A2 activity

Salam Ibrahim, Catherine Calzada, Valérie Pruneta-Deloche, Michel Lagarde, and Gabriel Ponsin

UMR 870 INSERM/INSA-Lyon, RMND, Régulations Métaboliques, Nutrition et Diabètes, Villeurbanne 69621

Corresponding Author: gabriel.ponsin{at}insa-lyon.fr

We have previously reported that VLDL could transfer phospholipids (PL) to platelets and that these transfers were favored by thrombin or lipoprotein lipase (LPL)- mediated platelet activation. The present work was undertaken to identify the platelet metabolic pathway involved in this process. The transfer of radiolabelled PL from VLDL (200 µM PL) to platelets (2x108/mL) was measured after incubations of 1 h at 37°C, with or without thrombin (0.1 U/mL) or LPL (500 ng/mL). To discriminate between metabolic pathways, various inhibitors, including aspirin, a cyclooxygenase inhibitor (300 µM), esculetin, a 12-lipoxygenase inhibitor (20 µM), Methyl-Arachidonyl-Fluorophosphonate (MAFP), a phospholipase A2 (PLA2) inhibitor (100 µM), 1,2-Bis (2-aminophenoxy) ethane-N,N,N’,N’-tetraacetic acid tetrakis (acetoxymethyl) ester (BAPTA-AM), an intracellular Ca2+ chelator (20 µM), bromoenol lactone (BEL), a Ca2+ independent-PLA2 (iPLA2) inhibitor (100 nM), or 1-[6-[[17ß-3-Methoxyestra-1,3,5(10)-trien-17-yl-]amino]hexyl]-1H-pyrrole-2,5-dione (U73122), a phospholipase C (PLC) inhibitor (20 µM), were added to the incubation medium. Aspirin and esculetin had no effect, showing that PL transfer was not directly dependent upon cyclooxygenase or lipoxygenase pathways. The transfer of PL was inhibited by MAFP, U73122 or BAPTA-AM. Although MAFP inhibits both cytosolic PLA2 (cPLA2) and iPLA2, only cPLA2 is a calcium- dependent enzyme. Since intracellular calcium mobilization is favored by PLC and inhibited by BAPTA-AM, our data suggest that the transfer of PL from VLDL to platelets results from a cPLA2 rather than a iPLA2- dependent process. This conclusion was confirmed by our observation that the inhibition of iPLA2 by BEL had no effect on PL transfers.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.